Chronic Myeloid Leukemia, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology.

Published

Journal Article

Chronic myeloid leukemia (CML) is defined by the presence of Philadelphia chromosome (Ph), resulting from a reciprocal translocation between chromosomes 9 and 22 [t(9;22] that gives rise to a BCR-ABL1 fusion gene. CML occurs in 3 different phases (chronic, accelerated, and blast phase) and is usually diagnosed in the chronic phase. Tyrosine kinase inhibitor (TKI) therapy is a highly effective first-line treatment option for all patients with newly diagnosed chronic phase CML (CP-CML). The selection TKI therapy should be based on the risk score, toxicity profile of TKI, patient's age, ability to tolerate therapy, and the presence of comorbid conditions. This manuscript discusses the recommendations outlined in the NCCN Guidelines for the diagnosis and management of patients with CP-CML.

Full Text

Duke Authors

Cited Authors

  • Radich, JP; Deininger, M; Abboud, CN; Altman, JK; Berman, E; Bhatia, R; Bhatnagar, B; Curtin, P; DeAngelo, DJ; Gotlib, J; Hobbs, G; Jagasia, M; Kantarjian, HM; Maness, L; Metheny, L; Moore, JO; Pallera, A; Pancari, P; Patnaik, M; Purev, E; Rose, MG; Shah, NP; Smith, BD; Snyder, DS; Sweet, KL; Talpaz, M; Thompson, J; Yang, DT; Gregory, KM; Sundar, H

Published Date

  • September 2018

Published In

Volume / Issue

  • 16 / 9

Start / End Page

  • 1108 - 1135

PubMed ID

  • 30181422

Pubmed Central ID

  • 30181422

Electronic International Standard Serial Number (EISSN)

  • 1540-1413

Digital Object Identifier (DOI)

  • 10.6004/jnccn.2018.0071

Language

  • eng

Conference Location

  • United States